Pasar al contenido principal

MECANISMOS DE PROLIFERACION Y RECAMBIO CELULAR DE CELULAS ENDOCRINAS NORMALES Y CANCEROSAS DE LA TIROIDES Y LA HIPOFISIS

PID2019-110437RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDADE DE SANTIAGO DE COMPOSTELA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe

  • Rodrigues, Joana S.
  • Chenlo, Miguel
  • Bravo, Susana B.
  • Pérez-Romero, Sihara
  • Suarez-Fariña, Maria
  • Sobrino, Tomás
  • Sanz-Pamplona, Rebeca
  • González-Prieto, Román
  • Blanco Freire, Manuel Narciso
  • Nogueiras, Ruben
  • López, Miguel
  • Fugazzola, Laura
  • Cameselle-Teijeiro, José Manuel
  • Álvarez, Clara V.
The E3 SUMO ligase PIAS2 is expressed at high levels in differentiated papillary thyroid carcinomas but at low levels in anaplastic thyroid carcinomas (ATC), an undifferentiated cancer with high mortality. We show here that depletion of the PIAS2 beta isoform with a transcribed double-stranded RNA-directed RNA interference (PIAS2b-dsRNAi) specifically inhibits growth of ATC cell lines and patient primary cultures in vitro and of orthotopic patient-derived xenografts (oPDX) in vivo. Critically, PIAS2b-dsRNAi does not affect growth of normal or non-anaplastic thyroid tumor cultures (differentiated carcinoma, benign lesions) or cell lines. PIAS2b-dsRNAi also has an anti-cancer effect on other anaplastic human cancers (pancreas, lung, and gastric). Mechanistically, PIAS2b is required for proper mitotic spindle and centrosome assembly, and it is a dosage-sensitive protein in ATC. PIAS2b depletion promotes mitotic catastrophe at prophase. High-throughput proteomics reveals the proteasome (PSMC5) and spindle cytoskeleton (TUBB3) to be direct targets of PIAS2b SUMOylation at mitotic initiation. These results identify PIAS2b-dsRNAi as a promising therapy for ATC and other aggressive anaplastic carcinomas., This work was supported by Agencia Estatal de Investigación (AEI, Spain), co-funded by the European Union, projects’ codes BFU2013-46109-R, BFU2016-76973-R, PID2019-110437RB-I00, PDC2021-121621-I00 and PID2022-140149OB-I00 to C.V.A. This work has received financial support from the Xunta de Galicia (Centro singular de investigación de Galicia accreditation 2019-2022) and the European Union (European Regional Development Fund - ERDF). J.M.C.-T. is supported by grant no. ISCIII-PI23/00722, and PI19/01316 from Instituto de Salud Carlos III, State Research Agency (Spain), co-funded by the European Union. L.F. is funded by Italian Ministry of Health - Ricerca Corrente. T.S. is recipient of a research contract from the Miguel Servet Program from the Instituto de Salud Carlos III, Ref. CPII17/00027, co-funded by the European Union., Peer reviewed